MarketPulse

SGX945

2 articles
BenzingaBenzinga··Prnewswire

Soligenix's SGX945 Earns UK Innovative Medicine Designation for Behçet's Disease

Soligenix's SGX945 earns UK Promising Innovative Medicine designation for Behçet's Disease, enabling early patient access with Phase 2 data showing 40% ulcer improvement.
SNGXrare diseaseBehçet's Disease
BenzingaBenzinga··Prnewswire

Soligenix Wins EMA Backing for SGX945 Orphan Drug Status in Behçet's Disease

Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.
SNGXrare diseaseclinical trial